Promega, CDI Collaborate on Stem Cell-Based Drug Toxicity Assays | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stem cell technology company Cellular Dynamics International and Madison, Wisconsin-based life sciences company Promega today announced plans to collaborate on validating predictive drug discovery toxicity tests that rely on CDI's induced pluripotent stem cells and cytotoxicity and cell viability assays from Promega.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.